Jane Meisel1, Chao Zhang2, Cameron Neely3, Pia Mendoza3, Shuo You4, Tatiana Han4, Yuan Liu2, Aysegul A Sahin5, Ruth O'Regan6, Xiaoxian Li7. 1. Department of Hematology and Oncology, Emory University, Atlanta, GA. 2. Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA. 3. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA. 4. Winship Institute, Emory University, Atlanta, GA. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. 6. Department of Medicine, University of Wisconsin, Madison, WI. 7. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA. Electronic address: xli40@emory.edu.
Abstract
INTRODUCTION: Hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancers without lymph node metastasis have good prognosis. We compared the prognosis of hormone receptor-positive, HER2-negative, lymph node-negative cancers with Oncotype DX score ranges of 1 to 10 (1-10 group) and 11 to < 18 (11-18 group). PATIENTS AND METHODS: A total of 107 cases in the 1-10 group and 225 cases in the 11-18 group were reviewed. All patients received surgery. The use of chemotherapy, radiotherapy, and endocrine therapy, and overall survival (OS), disease-free survival (DFS), and distant metastasis were compared between groups. RESULTS: There were no statistical differences in the use of chemotherapy (5.05% vs. 6.05%, P = .724) or radiotherapy (52.53% vs. 59.07%, P = .276) between the 1-10 group and the 11-18 group, respectively. The median OS and DFS were 47 and 45 months, respectively, in the 1-10 group, and 49 and 48 months in the 11-18 group. No significant difference was seen in OS (P = .995), DFS (P = .148), or rates of metastasis (P = .998). The 11-18 group had more death events and distant metastasis (death, 5 events; recurrence, 2 events; metastasis, 2 events) than the 1-10 group (death, 0 events; recurrence, 4 events; metastasis, 0 events). The majority of recurrences seen in both groups were in young patients who failed to comply with their endocrine therapy regimen. CONCLUSION: Patients in both the 1-10 group and the 11-18 group had good prognoses. Those who experienced recurrence were more likely to be premenopausal and to have failed to comply with the recommended endocrine therapy regimen. Endocrine therapy remains important in these patients.
INTRODUCTION:Hormone receptor-positive/humanepidermal growth factor receptor 2 (HER2)-negative breast cancers without lymph node metastasis have good prognosis. We compared the prognosis of hormone receptor-positive, HER2-negative, lymph node-negative cancers with Oncotype DX score ranges of 1 to 10 (1-10 group) and 11 to < 18 (11-18 group). PATIENTS AND METHODS: A total of 107 cases in the 1-10 group and 225 cases in the 11-18 group were reviewed. All patients received surgery. The use of chemotherapy, radiotherapy, and endocrine therapy, and overall survival (OS), disease-free survival (DFS), and distant metastasis were compared between groups. RESULTS: There were no statistical differences in the use of chemotherapy (5.05% vs. 6.05%, P = .724) or radiotherapy (52.53% vs. 59.07%, P = .276) between the 1-10 group and the 11-18 group, respectively. The median OS and DFS were 47 and 45 months, respectively, in the 1-10 group, and 49 and 48 months in the 11-18 group. No significant difference was seen in OS (P = .995), DFS (P = .148), or rates of metastasis (P = .998). The 11-18 group had more death events and distant metastasis (death, 5 events; recurrence, 2 events; metastasis, 2 events) than the 1-10 group (death, 0 events; recurrence, 4 events; metastasis, 0 events). The majority of recurrences seen in both groups were in young patients who failed to comply with their endocrine therapy regimen. CONCLUSION:Patients in both the 1-10 group and the 11-18 group had good prognoses. Those who experienced recurrence were more likely to be premenopausal and to have failed to comply with the recommended endocrine therapy regimen. Endocrine therapy remains important in these patients.
Authors: Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-23 Impact factor: 44.544
Authors: Amelia B Zelnak; Petros Nikolinakos; Jayanthi Srinivasiah; William Jonas; Andrew Pippas; Yuan Liu; Xiaoxian Li; Mylin Torres; Ruth M O'Regan Journal: Clin Breast Cancer Date: 2014-06-24 Impact factor: 3.225
Authors: Xiaoxian Li; Jing Yang; Limin Peng; Aysegul A Sahin; Lei Huo; Kevin C Ward; Ruth O'Regan; Mylin A Torres; Jane L Meisel Journal: Breast Cancer Res Treat Date: 2016-11-25 Impact factor: 4.872
Authors: Lyndsay N Harris; Nofisat Ismaila; Lisa M McShane; Fabrice Andre; Deborah E Collyar; Ana M Gonzalez-Angulo; Elizabeth H Hammond; Nicole M Kuderer; Minetta C Liu; Robert G Mennel; Catherine Van Poznak; Robert C Bast; Daniel F Hayes Journal: J Clin Oncol Date: 2016-02-08 Impact factor: 44.544
Authors: Xiaoxian Li; Jing Yang; Uma Krishnamurti; Lei Huo; Kevin C Ward; Ruth O'Regan; Limin Peng Journal: Clin Breast Cancer Date: 2017-04-28 Impact factor: 3.225
Authors: Betsy A Kohler; Recinda L Sherman; Nadia Howlader; Ahmedin Jemal; A Blythe Ryerson; Kevin A Henry; Francis P Boscoe; Kathleen A Cronin; Andrew Lake; Anne-Michelle Noone; S Jane Henley; Christie R Eheman; Robert N Anderson; Lynne Penberthy Journal: J Natl Cancer Inst Date: 2015-03-30 Impact factor: 13.506
Authors: Thi Truc Anh Nguyen; Lauren M Postlewait; Chao Zhang; Jane L Meisel; Ruth O'Regan; Sunil Badve; Kevin Kalinsky; Xiaoxian Li Journal: Breast Cancer Res Treat Date: 2022-01-27 Impact factor: 4.872
Authors: Vincent Geldhof; Laura P M H de Rooij; Liliana Sokol; Jacob Amersfoort; Maxim De Schepper; Katerina Rohlenova; Griet Hoste; Adriaan Vanderstichele; Anne-Marie Delsupehe; Edoardo Isnaldi; Naima Dai; Federico Taverna; Shawez Khan; Anh-Co K Truong; Laure-Anne Teuwen; François Richard; Lucas Treps; Ann Smeets; Ines Nevelsteen; Birgit Weynand; Stefan Vinckier; Luc Schoonjans; Joanna Kalucka; Christine Desmedt; Patrick Neven; Massimiliano Mazzone; Giuseppe Floris; Kevin Punie; Mieke Dewerchin; Guy Eelen; Hans Wildiers; Xuri Li; Yonglun Luo; Peter Carmeliet Journal: Nat Commun Date: 2022-09-20 Impact factor: 17.694